title: Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.
abstract: Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab.
authors.affiliation: Department of Medical oncology, AMC, Amsterdam, The Netherlands 
authors.forename: Stephanie O
authors.identifier: http://orcid.org/0000-0003-4129-0262
authors.initials: SO
authors.lastname: van der Woude
authors.affiliation: Department of Medical oncology, AMC, Amsterdam, The Netherlands 
authors.forename: Hanneke W M
authors.identifier: http://orcid.org/0000-0003-3546-9709
authors.initials: HW
authors.lastname: van Laarhoven
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007262:Infusions, Intravenous; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D042461:Vascular Endothelial Growth Factor A; D000096662:Ramucirumab